UK: Reinvestment-linked PBC (practice-based commissioning) only slightly off target:
This article was originally published in Clinica
Implementation in England of practice-based commissioning (PBC) arrangements, which feature incentives to develop new services, is only slightly behind schedule, but there is still some way to go to meet the completion target set for the end of 2006. At the end of June, 120 of England's 303 PCTs (40%, against a target of 45%) met the criterion "trajectory" related to PBC implementation, according to figures released today. This is up on May, which stood at 82 PCTs (27%, against a target of 29%). A major incentive of the PBC regime is that the "profits" from service provision can be retained for reinvestment specifically in facilities and equipment. "The planned trajectories must reach 100% by December," the Department of Health notes.
You may also be interested in...
ConMed Corp. is company of two halves ̶ general surgery and orthopedics – and is readying itself for a renewed assault on these two markets on the back of a technology pipeline, targeted acquisitions and a new growth-winning culture, says CFO Todd Garner.
Drug pricing and access issues expose the pharmaceutical sector especially acutely to calls for companies to meet ethical and social goals, alongside commercial ones. Digital is up-ending pharma’s processes, its workplaces and its consumers. R&D productivity is spluttering. Amid this turmoil, CEOs highlight company culture – the way an organization behaves – as a crucial ingredient for success. But what is a “right” culture? Organizational culture is neither static nor singular. It is continuously influenced by acquisitions, markets, new technologies and new generations. And pharma’s history suggests that culture change cannot happen without sufficient people change.